Search

Your search keyword '"Scheffold, Christian"' showing total 49 results
Start Over Author "Scheffold, Christian" Publication Year Range Last 10 years
49 results on '"Scheffold, Christian"'

1. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Author

Pal, Sumanta Kumar, Albiges, Laurence, Tomczak, Piotr, Suárez, Cristina, Voss, Martin H, de Velasco, Guillermo, Chahoud, Jad, Mochalova, Anastasia, Procopio, Giuseppe, Mahammedi, Hakim, Zengerling, Friedemann, Kim, Chan, Osawa, Takahiro, Angel, Martín, Gupta, Suyasha, Khan, Omara, Bergthold, Guillaume, Liu, Bo, Kalaitzidou, Melania, Huseni, Mahrukh, Scheffold, Christian, Powles, Thomas, and Choueiri, Toni K

Published
2023
Full Text
View/download PDF

3. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Author

Motzer, Robert J, Powles, Thomas, Burotto, Mauricio, Escudier, Bernard, Bourlon, Maria T, Shah, Amishi Y, Suárez, Cristina, Hamzaj, Alketa, Porta, Camillo, Hocking, Christopher M, Kessler, Elizabeth R, Gurney, Howard, Tomita, Yoshihiko, Bedke, Jens, Zhang, Joshua, Simsek, Burcin, Scheffold, Christian, Apolo, Andrea B, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

4. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Author

Schöffski, Patrick, Gordon, Michael, Smith, David C, Kurzrock, Razelle, Daud, Adil, Vogelzang, Nicholas J, Lee, Yihua, Scheffold, Christian, and Shapiro, Geoffrey I

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Anilides, Antineoplastic Agents, Belgium, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Early Termination of Clinical Trials, Female, Humans, Israel, Kaplan-Meier Estimate, Male, Neoplasms, Protein Kinase Inhibitors, Pyridines, Taiwan, Time Factors, Treatment Outcome, United States, Cabozantinib, Vascular endothelial growth factor receptor, Solid tumour, Objective response rate, Progression-free survival, Randomised discontinuation trial, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types.Cabozantinib was administered (100 mg, once daily) to patients with advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase.A total of 526 patients were enrolled. The highest ORR was observed in ovarian cancer (OC) (21.7%); the largest PFS benefit was observed in castration-resistant prostate cancer (CRPC) (median 5.5 versus 1.4 months for placebo; hazard ratio 0.14, 95% confidence interval: 0.04, 0.52). Disease control rates were >40% for CRPC, OC, melanoma, metastatic breast cancer (MBC), hepatocellular carcinoma (HCC) and non-small cell lung cancer. Median duration of response ranged from 3.3 (MBC) to 11.2 months (OC). Encouraging efficacy results and symptomatic improvements prompted early suspension of the randomised stage and conversion to open-label non-randomised expansion cohorts. Dose reductions to manage adverse events (AEs) occurred in 48.7% of patients. The most frequent grade III-IV AEs were fatigue (12.4%), diarrhoea (10.5%), hypertension (10.5%) and palmar-plantar erythrodysesthesia syndrome (8.7%).Clinical antitumour activity of cabozantinib was observed in a subset of tumour types: CRPC and OC were evaluated further in expansion cohorts. Phase III programs were initiated in CRPC and HCC. Interpretation of efficacy outcomes was limited by early termination of the randomised portion of the trial.NCT00940225.

Published
2017

7. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Author

Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, and Morris, Michael J.

Published
2018
Full Text
View/download PDF

8. Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

17. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

Author

Burotto, Mauricio, primary, Powles, Thomas, additional, Escudier, Bernard, additional, Apolo, Andrea B., additional, Bourlon, Maria Teresa, additional, Shah, Amishi Yogesh, additional, Suárez, Cristina, additional, Porta, Camillo, additional, Barrios, Carlos H., additional, Richardet, Martin, additional, Gurney, Howard, additional, Kessler, Elizabeth R, additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, George, Saby, additional, Scheffold, Christian, additional, Wang, Peter, additional, Fedorov, Viktor, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2023
Full Text
View/download PDF

18. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Author

Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Tannir, Nizar M, Mainwaring, Paul N, Rini, Brian I, Hammers, Hans J, Donskov, Frede, Roth, Bruce J, Peltola, Katriina, Lee, Jae Lyun, Heng, Daniel Y C, Schmidinger, Manuela, Agarwal, Neeraj, Sternberg, Cora N, McDermott, David F, Aftab, Dana T, Hessel, Colin, Scheffold, Christian, Schwab, Gisela, Hutson, Thomas E, Pal, Sumanta, and Motzer, Robert J

Published
2016
Full Text
View/download PDF

19. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

Author

Yau, Thomas, primary, Zagonel, Vittorina, additional, Santoro, Armando, additional, Acosta-Rivera, Mirelis, additional, Choo, Su Pin, additional, Matilla, Ana, additional, He, Aiwu Ruth, additional, Cubillo Gracian, Antonio, additional, El-Khoueiry, Anthony B., additional, Sangro, Bruno, additional, Eldawy, Tarek E., additional, Bruix, Jordi, additional, Frassineti, Giovanni Luca, additional, Vaccaro, Gina M., additional, Tschaika, Marina, additional, Scheffold, Christian, additional, Koopmans, Petra, additional, Neely, Jaclyn, additional, and Piscaglia, Fabio, additional

Published
2022
Full Text
View/download PDF

21. A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)

Author

Tolcher, Anthony, primary, Vandross, Andrae, additional, Johnson, Melissa, additional, Park, Haeseong, additional, Scheffold, Christian, additional, Li, Jing, additional, Bekele, Neby, additional, Uttamsingh, Shailaja, additional, Faggioni, Raffaella, additional, and Ulahannan, Susanna, additional

Published
2022
Full Text
View/download PDF

22. Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

Author

Suárez, Cristina, primary, Choueiri, Toni K., additional, Burotto, Mauricio, additional, Powles, Thomas, additional, Bourlon, Maria Teresa, additional, Shah, Amishi Yogesh, additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Escudier, Bernard, additional, Motzer, Robert J., additional, and Apolo, Andrea B., additional

Published
2022
Full Text
View/download PDF

23. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Author

Neal, Joel W., primary, Santoro, Armando, additional, Viteri, Santiago, additional, Ponce Aix, Santiago, additional, Fang, Bruno, additional, Lim, Farah Louise, additional, Gentzler, Ryan D., additional, Goldschmidt, Jerome H., additional, Khrizman, Polina, additional, Massarelli, Erminia, additional, Patel, Shiven B., additional, Puri, Sonam, additional, Sudhagoni, Ramu, additional, Scheffold, Christian, additional, Curran, Dominic, additional, and Felip, Enriqueta, additional

Published
2022
Full Text
View/download PDF

24. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Author

Yau, Thomas, Zagonel, Vittorina, Santoro, Armando, Acosta-Rivera, Mirelis, Choo, Su Pin, Matilla, Ana, He, Aiwu Ruth, Cubillo Gracian, Antonio, El-Khoueiry, Anthony B., Sangro, Bruno, Eldawy, Tarek E., Bruix, Jordi, Frassineti, Giovanni Luca, Vaccaro, Gina M., Tschaika, Marina, Scheffold, Christian, Koopmans, Petra, Neely, Jaclyn, and Piscaglia, Fabio

Published
2023
Full Text
View/download PDF

25. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

Author

Powles, Thomas, primary, Choueiri, Toni K., additional, Burotto, Mauricio, additional, Escudier, Bernard, additional, Bourlon, Maria Teresa, additional, Shah, Amishi Yogesh, additional, Suárez, Cristina, additional, Hamzaj, Alketa, additional, Porta, Camillo, additional, Hocking, Christopher, additional, Kessler, Elizabeth R, additional, Gurney, Howard, additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Apolo, Andrea B., additional, and Motzer, Robert J., additional

Published
2022
Full Text
View/download PDF

26. Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer

Author

Patnaik, Amita, primary, Barve, Minal, additional, Bhave, Manali, additional, Subbiah, Vivek, additional, Atwal, Sumandeep, additional, Sharma, Keerti, additional, Scheffold, Christian, additional, Wetmore, Cynthia, additional, and Shapiro, Geoffrey, additional

Published
2022
Full Text
View/download PDF

27. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Author

Pal, Sumanta K., primary, McGregor, Bradley, additional, Suárez, Cristina, additional, Tsao, Che-Kai, additional, Kelly, William, additional, Vaishampayan, Ulka, additional, Pagliaro, Lance, additional, Maughan, Benjamin L., additional, Loriot, Yohann, additional, Castellano, Daniel, additional, Srinivas, Sandy, additional, McKay, Rana R., additional, Dreicer, Robert, additional, Hutson, Thomas, additional, Dubey, Sarita, additional, Werneke, Scott, additional, Panneerselvam, Ashok, additional, Curran, Dominic, additional, Scheffold, Christian, additional, Choueiri, Toni K., additional, and Agarwal, Neeraj, additional

Published
2021
Full Text
View/download PDF

28. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Author

Choueiri, Toni K., Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N., Rini, Brian I., Donskov, Frede, Hammers, Hans, Hutson, Thomas E., Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J., Bjarnason, Georg A., Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C., Schmidinger, Manuela, Kantoff, Philip W., Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M., Tannir, Nizar M., and Motzer, Robert J.

Published
2015
Full Text
View/download PDF

30. Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

Author

Apolo, Andrea B., primary, Powles, Thomas, additional, Burotto, Mauricio, additional, Bourlon, Maria Teresa, additional, Hsieh, James J, additional, Basso, Umberto, additional, Shah, Amishi Yogesh, additional, Suarez, Cristina, additional, Porta, Camillo, additional, Barrios, Carlos H., additional, Gurney, Howard, additional, Kessler, Elizabeth R, additional, Retz, Margitta, additional, George, Saby, additional, Escudier, Bernard, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

31. Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

Author

Shah, Amishi Yogesh, primary, Motzer, Robert J., additional, Apolo, Andrea B., additional, Powles, Thomas, additional, Escudier, Bernard, additional, Zhang, Joshua, additional, Scheffold, Christian, additional, Karumanchi, Sravan, additional, Nguyen, Linh Thuy, additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

32. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Author

Motzer, Robert J., primary, Choueiri, Toni K., additional, Powles, Thomas, additional, Burotto, Mauricio, additional, Bourlon, Maria Teresa, additional, Hsieh, James J, additional, Maruzzo, Marco, additional, Shah, Amishi Yogesh, additional, Suarez, Cristina, additional, Barrios, Carlos H., additional, Richardet, Martin Eduardo, additional, Porta, Camillo, additional, Goh, Jeffrey C., additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Gupta, Saurabh, additional, and Apolo, Andrea B., additional

Published
2021
Full Text
View/download PDF

33. CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Author

Pal, Sumanta K., primary, Albiges, Laurence, additional, Suarez Rodriguez, Cristina, additional, Liu, Bo, additional, Doss, Jennifer, additional, Khurana, Sudha, additional, Scheffold, Christian, additional, Voss, Martin H, additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

35. Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Author

Tannir, Nizar M., primary, Powles, Thomas, additional, Escudier, Bernard, additional, Donskov, Frede, additional, Grünwald, Viktor, additional, Sternberg, Cora N., additional, Schmidinger, Manuela, additional, Schöffski, Patrick, additional, Szczylik, Cezary, additional, Peltolta, Katriina, additional, Nosov, Dmitry, additional, Melichar, Bohuslav, additional, Clary, Douglas, additional, Scheffold, Christian, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2020
Full Text
View/download PDF

37. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Author

Yau, Thomas, primary, Zagonel, Vittorina, additional, Santoro, Armando, additional, Acosta-Rivera, Mirelis, additional, Choo, Su Pin, additional, Matilla, Ana, additional, He, Aiwu Ruth, additional, Cubillo Gracián, Antonio, additional, El-Khoueiry, Anthony B., additional, Sangro, Bruno, additional, Eldawy, Tarek, additional, Bruix, Jordi, additional, Frassineti, Giovanni, additional, Vaccaro, Gina M., additional, Tschaika, Marina, additional, Scheffold, Christian, additional, Shen, Yun, additional, Neely, Jaclyn, additional, and Piscaglia, Fabio, additional

Published
2020
Full Text
View/download PDF

38. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Author

George, Daniel J., primary, Hessel, Colin, additional, Halabi, Susan, additional, Michaelson, M. Dror, additional, Hahn, Olwen, additional, Walsh, Meghara, additional, Picus, Joel, additional, Small, Eric J., additional, Dakhil, Shaker, additional, Feldman, Darren R., additional, Mangeshkar, Milan, additional, Scheffold, Christian, additional, Morris, Michael J., additional, and Choueiri, Toni K., additional

Published
2019
Full Text
View/download PDF

39. Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

Author

Choueiri, Toni K., primary, Hessel, Colin, additional, Halabi, Susan, additional, Sanford, Ben, additional, Michaelson, M. Dror, additional, Hahn, Olwen, additional, Walsh, Meghara, additional, Olencki, Thomas, additional, Picus, Joel, additional, Small, Eric J., additional, Dakhil, Shaker, additional, Feldman, Darren R., additional, Mangeshkar, Milan, additional, Scheffold, Christian, additional, George, Daniel, additional, and Morris, Michael J., additional

Published
2018
Full Text
View/download PDF

40. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Author

Choueiri, Toni K., primary, Apolo, Andrea B., additional, Powles, Thomas, additional, Escudier, Bernard, additional, Aren, Osvaldo Rudy, additional, Shah, Amishi, additional, Kessler, Elizabeth Riley, additional, Hsieh, James J, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, and Motzer, Robert J., additional

Published
2018
Full Text
View/download PDF

41. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

Author

Cella, David, primary, Escudier, Bernard, additional, Tannir, Nizar M., additional, Powles, Thomas, additional, Donskov, Frede, additional, Peltola, Katriina, additional, Schmidinger, Manuela, additional, Heng, Daniel Y.C., additional, Mainwaring, Paul N., additional, Hammers, Hans J., additional, Lee, Jae Lyun, additional, Roth, Bruce J., additional, Marteau, Florence, additional, Williams, Paul, additional, Baer, John, additional, Mangeshkar, Milan, additional, Scheffold, Christian, additional, Hutson, Thomas E., additional, Pal, Sumanta, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2018
Full Text
View/download PDF

42. Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.

Author

George, Daniel J., primary, Hessel, Colin, additional, Halabi, Susan, additional, Sanford, Ben L., additional, Michaelson, M. Dror, additional, Hahn, Olwen Mary, additional, Walsh, Meghara K., additional, Olencki, Thomas, additional, Picus, Joel, additional, Small, Eric Jay, additional, Dakhil, Shaker R., additional, Feldman, Darren R., additional, Mangeshkar, Milan, additional, Scheffold, Christian, additional, Morris, Michael J., additional, and Choueiri, Toni K., additional

Published
2018
Full Text
View/download PDF

44. Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).

Author

Tannir, Nizar M., primary, Powles, Thomas, additional, Escudier, Bernard J., additional, Donskov, Frede, additional, Grünwald, Viktor, additional, Sternberg, Cora N., additional, Schmidinger, Manuela, additional, Schoffski, Patrick, additional, Szczylik, Cezary, additional, Peltola, Katriina Johanna, additional, Nosov, Dmitry, additional, Melichar, Bohuslav, additional, Clary, Douglas O., additional, Scheffold, Christian, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2017
Full Text
View/download PDF

45. Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).

Author

Choueiri, Toni K., primary, Powles, Thomas, additional, Escudier, Bernard J., additional, Tannir, Nizar M., additional, Mainwaring, Paul, additional, Rini, Brian I., additional, Hammers, Hans J., additional, Donskov, Frede, additional, Roth, Bruce J., additional, Peltola, Katriina, additional, Lee, Jae-Lyun, additional, Heng, Daniel Yick Chin, additional, Schmidinger, Manuela, additional, Aftab, Dana T., additional, Hessel, Colin, additional, Scheffold, Christian, additional, Schwab, Gisela, additional, Pal, Sumanta K., additional, Hutson, Thomas E., additional, and Motzer, Robert J., additional

Published
2016
Full Text
View/download PDF

46. Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized,...

Author

Choueiri, Toni K., Albiges, Laurence, Tomczak, Piotr, Suárez, Cristina, Voss, Martin H., de Velasco, Guillermo, Chahoud, Jad, Procopio, Giuseppe, Mahammedi, Hakim, Zengerling, Friedemann, Kim, Chan, Gupta, Suyasha, Bergthold, Guillaume, Liu, Bo, Kalaitzidou, Melania, Huseni, Mahrukh A., Scheffold, Christian, Powles, Thomas, and Pal, Sumanta Kumar

Published
2023
Full Text
View/download PDF

47. Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort

Author

Basch, Ethan, primary, Autio, Karen A., additional, Smith, Matthew R., additional, Bennett, Antonia V., additional, Weitzman, Aaron L., additional, Scheffold, Christian, additional, Sweeney, Christopher, additional, Rathkopf, Dana E., additional, Smith, David C., additional, George, Daniel J., additional, Higano, Celestia S., additional, Harzstark, Andrea L., additional, Sartor, A. Oliver, additional, Gordon, Michael S., additional, Vogelzang, Nicholas J., additional, de Bono, Johann S., additional, Haas, Naomi B., additional, Corn, Paul G., additional, Schimmoller, Frauke, additional, and Scher, Howard I., additional

Published
2015
Full Text
View/download PDF

48. Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Author

Smith, Matthew R., primary, Sweeney, Christopher J., additional, Corn, Paul G., additional, Rathkopf, Dana E., additional, Smith, David C., additional, Hussain, Maha, additional, George, Daniel J., additional, Higano, Celestia S., additional, Harzstark, Andrea L., additional, Sartor, A. Oliver, additional, Vogelzang, Nicholas J., additional, Gordon, Michael S., additional, de Bono, Johann S., additional, Haas, Naomi B., additional, Logothetis, Christopher J., additional, Elfiky, Aymen, additional, Scheffold, Christian, additional, Laird, A. Douglas, additional, Schimmoller, Frauke, additional, Basch, Ethan M., additional, and Scher, Howard I., additional

Published
2014
Full Text
View/download PDF

49. Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.

Author

Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, and Felip E

Abstract

Introduction: We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI)., Methods: COSMIC-021 (NCT03170960) is a phase 1b, multicenter study in advanced solid tumors. This analysis included patients with stage IV non-squamous NSCLC without actionable genomic aberrations in EGFR, ALK, ROS1 , or BRAF - V600E who progressed on one prior ICI and less than or equal to two prior lines of systemic anticancer therapy. Patients received cabozantinib 40 mg orally/day plus atezolizumab 1200 mg intravenously every three weeks (combination cohort) or cabozantinib 60 mg orally/day (single-agent cabozantinib cohort). Primary end point of the combination cohort was objective response rate per Response Evaluation Criteria in Solid Tumors v1.1 by investigator. Outcomes in the single-agent cabozantinib cohort were exploratory., Results: Eighty-one patients assigned to combination therapy and 31 assigned to single-agent cabozantinib received greater than or equal to one dose of study treatment. Median (range) follow-up was 26.1 months (12.1-44.2) and 22.4 months (1.5-29.0), respectively. Objective response rate was 20% (95% confidence interval: 11.7%-30.1%) in combination cohort and 6% (95% confidence interval: 0.8%-21.4%) in single-agent cabozantinib cohort. Treatment-related adverse events (TRAEs) occurred in 86% of patients in the combination cohort and 90% in the single-agent cabozantinib cohort; grade 3/4 TRAEs were 44% and 48%, respectively. There were two grade 5 TRAEs: pneumonitis (n = 1, combination) and gastric ulcer hemorrhage (n = 1, single-agent). Neither PD-L1 expression in tumor cells nor tumor mutation burden correlated with outcomes., Conclusions: Cabozantinib plus atezolizumab demonstrated modest clinical activity and manageable toxicity in advanced NSCLC after progression on prior ICI., Competing Interests: Dr. Neal reported receiving honoraria from Biomedical Learning Institute CME, Clinical Care Options, CME Matter, Medscape CME, MJH Life Sciences CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Research to Practice CME, Rockpointe CME, Medical Educator Consortium, HMP Education, a consulting or advisory role with AstraZeneca, Blueprint Pharmaceuticals, Calithera Biosciences, D2G Oncology, Exelixis, Genentech, Roche, Jounce Therapeutics, Eli Lilly and Company, Natera, Regeneron, Sanofi, Surface Oncology, Takeda Pharmaceuticals, Turning Point Therapeutics, and receiving institutional research funding from 10.13039/100006483AbbVie, Adaptimmune, Boehringer Ingelheim, 10.13039/100010544Exelixis, 10.13039/100004328Genentech, 10.13039/100004337Roche, GSK, 10.13039/100005565Janssen, 10.13039/100004334Merck, Nektar Therapeutics, 10.13039/100004336Novartis, Takeda Pharmaceuticals. Dr. Armando Santoro reported having a consulting or advisory role with Sanofi, Incyte, receiving honoraria from AbbVie, Amgen, ArQule, AstraZeneca, Bayer, BMS, Celgene, Eisai, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Servier, Takeda, and participating in a data safety or advisory board with BMS, Servier, Gilead, Pfizer, Eisai, Bayer, MSD. Dr. Maria Gonzalez-Cao reported receiving grants or contracts from Roche, AstraZeneca, and Novartis, honoraria from Bristol Myers Squibb, MSD, AstraZeneca, Novartis, and Pierre Fabre, support for travel, accommodations, and expenses from MSD, AstraZeneca, and Pierre Fabre, and having a leadership or fiduciary role with the Spanish Melanoma Group. Dr. Ryan D. Gentzler reported receiving honoraria from Targeted Oncology, OncLive, Clinical Care Options, Society for Immunotherapy of Cancer, American Society of Clinical Oncology, MedStar Health, Aptitude Health, support for attending meetings from International Association for the Study of Lung Cancer, American Society of Clinical Oncology, Dava Oncology, Tempus, having a consulting or advisory role with AstraZeneca, Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Mirati Therapeutics, OncoCyte, Sanofi, Takeda, Merus, Regeneron, receiving institutional research funding from 10.13039/100002429Amgen, Alliance Foundation, 10.13039/100004325AstraZeneca, Big Ten Research Consortium, 10.13039/100002491Bristol Myers Squibb, 10.13039/100010795Chugai, 10.13039/501100022274Daiichi Sankyo, 10.13039/100008130Helsinn Therapeutics, Hoosier Cancer Research Network, 10.13039/100005565Janssen, 10.13039/100016765Jounce Therapeutics, Merck, 10.13039/100016957Mirati Therapeutics, 10.13039/100004319Pfizer, 10.13039/100008199RTI International, Takeda, Dizal, Puma, and having leadership or committee roles with Hoosier Cancer Research Network, ASCO, Journal of Clinical Oncology, NCI Investigational Drug Steering Committee, and International Association for the Study of Lung Cancer. Dr. Jerome Goldschmidt reported receiving honoraria from G1 Therapeutics, and support for travel, accommodations, and expenses from Sara Cannon Research Institute. Dr. Claudia Proto reports receiving honoraria from AstraZeneca, Bristol Myers Squibb, MSD, Roche, Sanofi, having a consulting or advisory role with AstraZeneca, MSD and Roche, institutional research funding from MSD, Lilly, Pfizer, support for travel, accommodations, expenses from AstraZeneca, MSD, and Roche, and is the principal investigator in clinical trials for Janssen, Pfizer, Lilly, Spectrum Pharmaceuticals, Roche, MSD, BMS, and AstraZeneca. Dr. Shiven Patel reported receiving a consulting or advisory role with AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Regeneron, Sanofi, TerSera Therapeutics LLC, Total Health Conferencing, Natera, Takeda, Merck, BMS, and receiving institutional research funding from AstraZeneca, Janssen, Merck, and Takeda. Dr. Sonam Puri reported having an institutional consulting or advisory role with Jazz Pharma, receiving consulting fees from G1 Therapeutics, Pfizer, Bristol-Myers Squibb, receiving honoraria from Aptitude Health, and support for travel, accommodations, and expenses from Dava Oncology. Dr. Stephen V. Liu reported having a consulting or advisory role with AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech, Roche, Gilead Sciences, Guardant Health, Janssen Oncology, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics, receiving institutional research funding from AbbVie, 10.13039/100018529Alkermes, Elevation Oncology, Ellipses, Genentech, Roche, 10.13039/100005564Gilead Sciences, Merck, Merus, Nuvalent, Inc., RAPT Therapeutics, and Turning Point Therapeutics, and participation in a data safety monitoring board or advisory board with Candel Therapeutics. Dr. Erminia Massarelli reported receiving honoraria from AstraZeneca, Merck, Eli Lilly and Company, Takeda Pharmaceuticals, Mirati, and having a consulting or advisory role with Bristol Myers Squibb, Daiichi Sankyo Co., Fusion Therapeutics, Janssen, Eli Lilly and Company, Sanofi, AbbVie, Iovance Therapeutics, and Mirati. Ms. Denise Williamson, Drs. Martin Schwickart, Christian Scheffold, and Svetlana Adrianova are employees of and reported having stock with Exelixis. In addition, Dr. Christian Scheffold reported a patent: Combinations of Cabozantinib and Atezolizumab to Treat Cancer; patent number 11198731. Dr. Enriqueta Felip reported having a consulting or advisory role with AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Gilead, GlaxoSmithKline, Janssen, Merck Serono, MSD, Novartis, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Turning Point, Daiichi Sankyo, honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, MSD, Peervoice, Pfizer, Sanofi, Takeda, Touch Oncology, and receiving support for travel, accommodations, and expenses from AstraZeneca, Janssen, Roche. The remaining authors declare no conflict of interest., (© 2024 The Authors.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results